相关实验视频

Updated: Jun 3, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

达拉图马布和罗米普洛斯蒂姆联合治疗长期耐火性原发性免疫性血小板缺血症 - 病例报告

Ibrahim Zoubi¹, Amir Warwar^1,2, Shoshan Perek¹

¹Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel.

ImmunoTargets and therapy

|January 13, 2025

概括

多重耐药性免疫血小板缺血症 (ITP) 需要新的治疗方法. 在难以治疗的ITP病例中,将达拉图穆马布与罗米普洛斯蒂姆结合使用提供了持久的反应.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

多重耐药性免疫血小板缺血症 (ITP) 呈现出显著的发病率和死亡率.
标准的单剂疗法往往不足以治疗慢性,耐火性ITP.
了解ITP的发病因子对于开发有效的治疗策略至关重要.

研究的目的:

评估多重耐药ITP的组合治疗的疗效和安全性.
探索一种双剂方法来解决免疫破坏和血小板生产的问题.

主要方法:

一个67岁的女性患有长期多重耐火性ITP的案例研究.
治疗涉及达拉图穆马布和罗米普洛斯蒂姆的组合.
达拉图穆马布在诱导和维护阶段进行;罗米普洛司姆每周一次,剂量进行调整.

主要成果:

达到了持续超过42周的持久反应.
证明成功的血小板计数管理.
用组合治疗表明长时间反应的潜力.

结论:

达拉图穆马布和罗米普洛斯蒂姆的联合治疗可以有效治疗多重耐火性ITP.
这种双剂方法可以克服单剂治疗的局限性.
需要进一步研究与TPO-RAs扩展的,较少频繁的Daratumumab剂量.

关键词:

在TPO模仿剂中使用的模仿剂.抗CD38定向疗法抗CD38定向治疗案例报告案例报告多重耐药性免疫性血小板缺血症.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.